12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MOB-015: Completed Phase II enrollment

Moberg completed enrollment of 25 patients in a Swedish Phase II trial evaluating once-daily topical MOB-015 for 12 months. In February 2012, the company said an analysis of 50% of patients in...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >